pharmaceuticals
Healthcare
Jubilant Life Sciences to split pharma, life science ingredient businesses
Noida-based Jubilant Life Sciences Ltd plans to demerge its pharmaceuticals and life science ingredient businesses as part of its second ......
Healthcare
OrbiMed-backed Eurolife acquires Teva's European intravenous infusion plant
Indian pharmaceuticals firm Eurolife Healthcare Pvt. Ltd on Friday said it has acquired the European intravenous infusions plant of Israel-based ......
Healthcare
M&A activity in healthcare softens, PE dealmaking steady in Q2
Merger and acquisition activity in India's healthcare sector has slowed in recent quarters from last year when Malaysian company IHH ......
Healthcare
NCLAT stays liquidation of Sterling Biotech
The National Company Law Appellate Tribunal (NCLAT) has stayed the order of a lower bankruptcy court which had referred debt-laden ......
Healthcare
How much did SAIF Partners, ChrysCapital make from stake sale in drugmaker?
Venture capital and growth-equity investor SAIF Partners as well as private equity firm ChrysCapital have sold stakes in an Indian ......
Healthcare
Quadria Capital hits the road for new healthcare PE fund
Quadria Capital, a private equity firm which focuses on South- and Southeast Asia, has hit the road to raise its ......
Finance
ChrysCapital checks out of PIPE portfolio firm with high returns
Homegrown private equity firm ChrysCapital has fully exited a company it had backed less than four years ago in its ......
Healthcare
Five trends to watch out for in healthcare sector in 2018
The healthcare sector is poised for an eventful 2018 as medical devices and pharmaceutical firms await key policy announcements, more ......
General
Flashback 2017: Top M&As of the year
Merger and acquisition activity in India eased this year, with deal volume falling to a four-year low and several high-profile ......
Healthcare
Flashback 2017: Pharma M&As hog limelight; multi-speciality hospitals get PE money
Large private equity investments in multi-specialty hospitals and sustained investor interest across the single-specialty space were the showstoppers in the ......
